Literature DB >> 29318563

Generation of Highly Selective MMP Antibody Inhibitors.

Dong Hyun Nam1, Xin Ge2.   

Abstract

Inhibiting individual MMPs of biomedical importance with high selectivity is critical for both fundamental research and therapy development. Here we describe the methods for discovery of inhibitory monoclonal antibodies from synthetic human antibody phage display libraries carrying convex paratopes encoded by long complementarity-determining region (CDR)-H3 segments. We demonstrate the application of this technique for isolation of highly specific and potent antibody inhibitors of human MMP-14.

Entities:  

Keywords:  Convex paratope; Inhibitory antibody; Long CDR; Synthetic library

Mesh:

Substances:

Year:  2018        PMID: 29318563      PMCID: PMC5901970          DOI: 10.1007/978-1-4939-7595-2_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  34 in total

Review 1.  Matrix metalloproteinase proteomics: substrates, targets, and therapy.

Authors:  Charlotte J Morrison; Georgina S Butler; David Rodríguez; Christopher M Overall
Journal:  Curr Opin Cell Biol       Date:  2009-07-16       Impact factor: 8.382

Review 2.  New approaches for dissecting protease functions to improve probe development and drug discovery.

Authors:  Edgar Deu; Martijn Verdoes; Matthew Bogyo
Journal:  Nat Struct Mol Biol       Date:  2012-01-05       Impact factor: 15.369

3.  Refolding of the catalytic and hinge domains of human MT1-mMP expressed in Escherichia coli and its characterization.

Authors:  Hyun Min Koo; Joo-Hyon Kim; In Kwan Hwang; Seo-Jin Lee; Tae-Han Kim; Ki-Hyeong Rhee; Seung-Taek Lee
Journal:  Mol Cells       Date:  2002-02-28       Impact factor: 5.034

4.  Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.

Authors:  Karl R Schmitz; Atrish Bagchi; Rob C Roovers; Paul M P van Bergen en Henegouwen; Kathryn M Ferguson
Journal:  Structure       Date:  2013-06-20       Impact factor: 5.006

5.  Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential.

Authors:  Netta Sela-Passwell; Raghavendra Kikkeri; Orly Dym; Haim Rozenberg; Raanan Margalit; Rina Arad-Yellin; Miriam Eisenstein; Ori Brenner; Tsipi Shoham; Tamar Danon; Abraham Shanzer; Irit Sagi
Journal:  Nat Med       Date:  2011-12-25       Impact factor: 53.440

Review 6.  Matrix metalloproteinases: protective roles in cancer.

Authors:  Julie Decock; Sally Thirkettle; Laura Wagstaff; Dylan R Edwards
Journal:  J Cell Mol Med       Date:  2011-06       Impact factor: 5.310

7.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  2,4,6-Trinitrotoluene detection using recombinant antibodies.

Authors:  Ellen R Goldman; Andrew Hayhurst; Brian M Lingerfelt; Brent L Iverson; George Georgiou; George P Anderson
Journal:  J Environ Monit       Date:  2003-06

9.  Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?

Authors:  Stanley Zucker; Jian Cao
Journal:  Cancer Biol Ther       Date:  2009-12-19       Impact factor: 4.742

Review 10.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

View more
  3 in total

Review 1.  Inhibition of MMPs and ADAM/ADAMTS.

Authors:  Charles J Malemud
Journal:  Biochem Pharmacol       Date:  2019-02-28       Impact factor: 5.858

2.  Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies.

Authors:  Dong Hyun Nam; Ki Baek Lee; Evan Kruchowy; Henry Pham; Xin Ge
Journal:  Biochemistry       Date:  2020-09-30       Impact factor: 3.162

3.  Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.

Authors:  N Sevillano; M F Bohn; M Zimanyi; Y Chen; C Petzold; S Gupta; C Y Ralston; C S Craik
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-11-19       Impact factor: 3.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.